How a drug development plan can save your biotech money
The drug development industry has seen a major shift of clinical activity away from large pharmaceutical companies in favour of…
Accelerating Clinical Trials
Latest in
Accelerating Clinical Trials
Partner content
The benefit of running clinical trials in Asia-Pacific for biotech companies
According to Frost & Sullivan, the CRO market is forecast to grow to US$ 71.7billion by 2024 (+8% CAGR 19-24F).…
Partner content
Is Australia the future for successful first-in-human clinical studies?
The number of biotech-sponsored clinical trials in Australia has grown by more than +10% on average each year between 2017…
Partner content
How biotechs can tap APAC for excellence in oncology trials
Asia-Pacific biotech specialist CRO Novotech has released a new webinar about the advantages of conducting oncology clinical trials in the…
Partner content
Why Asia-Pacific attracts 60% of all ongoing and planned hepatology trials globally
There are more than 1,300 clinical trials in hepatology, either ongoing or planned, in Asia-Pacific. This represents about 60% of…
Partner content
Clinical Trial Continuity in Asia-Pacific during the COVID-19 pandemic
The leading Asia-Pacific biotech specialist CRO Novotech is releasing a series of webinars about the advantages of conducting clinical trials…
Partner content
Biotechs testing for COVID-19 in Asia-Pacific benefit from new fast-track review processes
Many countries in the Asia-Pacific region are now fast-tracking their COVID-19 clients’ clinical trials with expedited review processes for treatment…
Partner content
Data shows majority of Australian sites are open for clinical trial activity
Novotech, the Asia-Pacific CRO, has published data detailing the current status of clinical trials in the Asia-Pacific region during the…